Advances in Personalized Medicine for Locally Advanced Upper GI Adenocarcinomas

Personalized medicine has been gaining momentum in recent years, particularly in the treatment of locally advanced upper gastrointestinal (GI) adenocarcinomas. Despite aggressive treatment, these cancers continue to pose a major global health concern, with poor overall survival and high recurrence rates. Recent studies have highlighted the need for more effective strategies, including the integration of HER2-targeted therapies and immunotherapy.

Key Takeaways:

• Upper GI malignancies, including esophageal, gastroesophageal junction (GEJ), and gastric adenocarcinomas, remain a major global health concern.
• Patients with very early tumors (cT1a) can benefit from endoscopic therapy, while those with locally advanced disease require multimodal therapies combining surgery, radiation, and systemic therapies.
• Surgical resection remains the cornerstone of curative treatment, with perioperative chemotherapy emerging as the standard of care.
• Preoperative chemoradiation has demonstrated some benefits in esophageal and GEJ cancers, but recent data suggest a more limited role for radiation going forward.
• Immunotherapy has shown promise in both the adjuvant and perioperative settings, but has yet to establish definitive survival benefit.
• Additional authors contributing to this research include Mariela Blum Murphy, Jaffer A. Ajani, Jane E. Rogers, Rebecca E. Waters, and Qiong Gan.

Statistics:

• Locally advanced upper GI adenocarcinomas account for a significant proportion of global cancer-related deaths (Cancer, 2025;17(8):1307).
• Perioperative chemotherapy has emerged as a standard of care for locally advanced upper GI adenocarcinomas (Cancer, 2025;17(8):1307).
• The integration of HER2-targeted therapies into treatment regimens has not yielded significant improvements in Her2-positive locally advanced gastroesophageal cancers (Cancer, 2025;17(8):1307).

Sources:

• Cancers, 2025;17(8):1307 - Evolution of Therapeutics for Locally Advanced Upper Gastrointestinal Adenocarcinoma
• United States, North and Central America, Adenocarcinoma, Cancer, Drugs and Therapies, Gastroenterology, Health and Medicine, Oncology, Personalized Medicine, Personalized Therapy, University of Texas MD Anderson Cancer Center.